ReviewBMC women's health2026

Sacituzumab govitecan combined with tislelizumab as second-line therapy for recurrent or metastatic cervical cancer: a case report and literature review.

Hui Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.